GlassScriptPhysician profile
Dominick J Angiolillo
NPI 1578687844
$386,895.42
in general payments reported to CMS, 2019-2025
24 companies · $72K in 2025
The $72K reported for 2025 was more than what 98% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119K · 2020: $66K · 2021: $30K · 2022: $19K · 2023: $66K · 2024: $15K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $112K · Travel and Lodging: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,600 · Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $111,673.50 |
| Travel and Lodging | $32,575.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,600.00 |
| Food and Beverage | $1,022.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $114,803.05 | 2019-2025 | |
| Chiesi USA, INC. | $81,030.21 | 2019-2025 | Kengreal |
| E.R. Squibb & Sons, L.L.C. | $43,134.95 | 2019-2025 | |
| Amgen INC. | $31,198.16 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $20,678.87 | 2023-2025 | Leqvio |
| Janssen Scientific Affairs, LLC | $19,310.18 | 2020-2024 | |
| Boehringer Ingelheim International Gmbh | $18,155.80 | 2019-2020 | |
| Janssen Research & Development, LLC | $15,112.63 | 2023-2025 | |
| Astrazeneca Uk Limited | $11,474.55 | 2019-2020 | |
| Csl Behring | $9,295.00 | 2020-2023 | |
| Eli Lilly and Company | $7,600.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $5,370.00 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $2,500.00 | 2023 | Selatogrel |
| Accriva Diagnostics INC. | $2,200.00 | 2025 | |
| Lilly USA, LLC | $1,752.00 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharma Ag | $1,710.91 | 2022 | |
| Abbott Laboratories | $1,250.00 | 2020 | |
| Acist Medical Systems, INC. | $179.08 | 2025 | |
| Edwards Lifesciences Corporation | $80.67 | 2019 | |
| Novo Nordisk INC | $59.36 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominick Angiolillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.